TABLE I.
Clinico-Pathological Parameters
| Patient characteristics | Mean n (% or media; range) |
|---|---|
| Age at surgery (years) | 65.0 (65.5, 44.0–76.8) |
| Pre-operative PSA (n = 70) | |
| Total PSA value (ng/ml) | 13 (8, 1–90) |
| PSA ≤ 10 ng/ml | 43 (61.4) |
| PSA > 10 ng/ml | 27 (38.6) |
| Follow-up (years) | 10.26 (1.74–19.68) |
| Gleason sum (n = 99) | 7 (7, 4–10)a |
| GS ≤ 6 | 36 (36.4) |
| GS = 7 | 37 (37.4) |
| GS = 3 + 4 | 31 (31.3) |
| GS = 4 + 3 | 6 (6.1) |
| GS ≥ 8 | 26 (26.3) |
| Pathologic stage (n = 100) | |
| pT2 | 34 (34.0) |
| pT3a | 51 (51.0) |
| pT3b | 5 (5.0) |
| pT3c | 6 (6.0) |
| pT4 | 4 (4.0) |
| Tumor volume, ml3 (n = 85) | 7 (5, 0–35)a |
| Lymph node involvement (n = 95) | |
| Yes | 4 (4.2)a |
| No | 91 (95.8)a |
| Extracapsular extension (n = 100) | |
| Yes | 66 (66.0) |
| No | 44 (44.0) |
| Surgical margin involvement (n = 100) | |
| Yes | 52 (52.0) |
| No | 48 (48.0) |
| Adjuvant treatment post-RP (n = 28) | |
| Endocrine therapy | 23 (23.0) |
| Radiotherapy alone | 2 (2.0) |
| Radiotherapy + endocrine | 3 (3.0) |
| Biochemical recurrence (n = 93) | |
| Yes | 33 (35.5)a |
| No | 60 (64.5)a |
| Local recurrence (n = 100) | |
| Yes | 4 (4.0) |
| No | 96 (96.0) |
| Distant metastases (n = 100) | |
| Yes | 33 (33.0) |
| No | 67 (67.0) |
| Overall death (n = 100) | |
| Yes | 28 (28.0) |
| No | 72 (72.0) |
| Prostate cancer specific mortality (n = 100) | |
| Yes | 21 (21.0) |
| No | 79 (79.0) |
PSA, prostate specific antigen.
a
Not all cases have available information.